The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this series of reports, we present a comprehensive analysis of current and emerging chimeric antigen receptor (CAR) T-cell therapies. We examine the CAR T-cell treatment landscape: the technology behind it, ongoing clinical development, the challenges, pricing and market access, physicians’ views, and future opportunities for this paradigm-shifting treatment approach.
How is CAR T-cell therapy being adopted into medical practice? What kind of referral patterns are in place for potentially eligible patients? What is the typical patient journey for a patient receiving CAR T-cell therapy?
What kind of support and training programs for Kymriah and Yescarta are in place for healthcare professionals, patients, and caregivers?
What are the key pricing, access, and reimbursement issues facing Kymriah and Yescarta? What novel reimbursement strategies are marketers implementing to ensure market access?
What challenges remain and could limit widespread and maximum adoption of autologous CD19-targeted CAR T-cell therapies? What are the future directions and opportunities?
What are the notable developments in the pipeline? Who are the key players, and what novel targets are they exploring?
Special Topics Report Series: Is a three-wave series based on KOL interviews conducted at about one, six, and twelve months postcommercialization and on secondary data collected from a variety of sources. We capture physicians’ awareness, perception, and use of the launched product and anticipated future trends.
Markets covered: United States
Primary research: Qualitative interviews with ten U.S. hematologist-oncologists and thought leaders for the three waves.
Key metrics included:
Physician familiarity with and impressions of Kymriah, Yescarta, and other CAR T-cell therapies in the pipeline.
Referral patterns, patient journey, and certification of treatment centers.
Current manufacturing and scalability challenges.
Marketing and educational programs for patients, healthcare professionals, and caregivers.
Cost of CAR T-cell therapy and novel pricing and market access strategies.
Timeline for Administration of Kymriah Therapy for B-Cell ALL
Results from Key Clinical Trials of Kymriah in the Treatment of B-Cell ALL and DLBCL
Expert Insights on Kymriah
Patient Journey and Referral Patterns for Kymriah Therapy for B-Cell ALL Patients
Expert Insights on the Patient Journey and Referral Patterns for Kymriah
Support and Training Programs for Kymriah
Expert Insights on the Support and Training Programs for Kymriah
Pricing, Access, and Reimbursement for Kymriah
Expert Insights on Pricing, Access, and Reimbursement for Kymriah
Ongoing Clinical Development of Kymriah
Key Ongoing Clinical Trials of Kymriah
Yescarta (Axicabtagene Ciloleucel)
Timeline for Administration of Yescarta Therapy for Large B-Cell Lymphoma
Results of Key Clinical Trials Investigating Yescarta for the Treatment of NHL
Expert Insights on Yescarta
Support and Training Programs for Yescarta
Expert Insights on the Support and Training Programs for Yescarta
Pricing, Access, and Reimbursement for Yescarta
Expert Insights on Pricing, Access, and Reimbursement for Yescarta
Ongoing Clinical Development of Yescarta
Key Ongoing Clinical Trials of Yescarta
Choosing Between Kymriah and Yescarta
Physiciansu2019 Choice Between Kymriah and Yescarta
Choosing Between Kymriah and Yescarta for Adult Patients with Large B-Cell Lymphoma
CAR T-Cell Therapy Pipeline
Notable Developments in the Pipeline
CAR T-Cell Therapies in Clinical Development
Expert Insights on the CAR T-Cell Pipeline
Challenges and Future Directions
Challenges Facing Current CD19-Targeted CAR T-Cell Therapies
Future Directions and Opportunities for CAR T-Cell Therapies
Expert Insight on the Challenges and Future Directions of CAR T-Cell Therapy
Key Abbreviations Related to CAR T-Cell Therapy
CAR T-Cell Therapy Bibliography
Ed Cortellini is a Business Insights Analyst in the Oncology group at Decision Resources Group. He joined DRG in January 2012 as a Data Analyst. He has produced quantitative & statistical analysis across all DRG products which include but are not limited to unmet needs, current treatment, access and reimbursement, patient profiler, and emerging therapies.